TG Therapeutics | TGTX - Net Income


TG Therapeutics reported $23.04M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Alaunos Therapeutics USD -1.16M 417K Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Ardelyx USD -969K 18.11M Sep/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
Bayer EUR -963M 764M Sep/2025
Biogen USD 466.5M 168.3M Sep/2025
Corcept Therapeutics USD 24.29M 4.62M Dec/2025
Curis USD -11.8M 80K Jun/2024
Gilead Sciences USD 2.18B 869M Dec/2025
Infinity Pharmaceuticals USD -9.96M 1.09M Jun/2023
J&J USD 5.12B 36M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Novartis USD 3.93B 96M Sep/2025
Novavax USD -121.3M 283.68M Sep/2024
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
TG Therapeutics USD 23.04M 367.86M Dec/2025
Verastem USD -8.26M 25.61M Jun/2024
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025